Adipose dysfunction contributes to age-related systemic decline primarily through its adverse effects on energy metabolism, insulin sensitivity, circulating adipokines, and inflammation. Time-restricted feeding (TRF) has emerged as a promising approach to correct adipose and metabolic dysfunction. However, most of these studies were carried out in young animals. Whether TRF could exert similar beneficial effects in the adipose tissue during aging remains unknown. To address this, 18-month-old...

CONCLUSIONS: An HTA-derived PBA reliably differentiates TORS expertise, aligns with speed and margin quality, and identifies lateral tasks as high-yield training targets. These metrics support standardized training, assessment, and integration into VR simulation for competency-based credentialing.

Quemliclustat potently inhibits CD73, a key enzyme producing immunosuppressive adenosine. In a phase 1b trial (ARC-8), we evaluated safety and efficacy of quemliclustat combined with gemcitabine/nab-paclitaxel (G/nP) with or without zimberelimab (anti-programmed cell death protein 1 (PD-1)) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). During the dose-escalation phase, 22 patients were enrolled across five dose levels of quemliclustat (25 mg, 50 mg, 75 mg, 100 mg or 125 mg)...

CONCLUSIONS: At 2024 pricing, and from a U.S. hospital perspective, ES/MMAE for cSDH may not be cost-effective within a 180-day horizon, but PSA suggests a greater favorability towards ES/MMAE at higher willingness-to-pay thresholds. The positive net QALY benefit with adjunctive MMAE for cSDH suggests a small but meaningful quality-of-life improvement, preventing complete ES dominance. Cost-reduction strategies, longer time frames, and validated cSDH-specific patient-reported outcome measures...

No abstract